The landscape of neuroscience drug development is evolving rapidly, marked by groundbreaking innovations, complex regulatory shifts, and an urgent demand for more targeted therapies.
We are pleased to invite you to view the exclusive Beacon Neuroscience fireside chat, where we’ll explore these trends in depth with one of the field’s leading voices, Dr. Bruce Morimoto, Head of Drug Development at Fuku Biotech.
This thought-provoking session will uncover where the greatest opportunities lie, what roadblocks persist, and how R&D leaders can strategically navigate the future of neurotherapeutics.
Key Insights:
- Introduction to Scatter-Free Absorption (SFA) technology – a new way to quantify payloads in intact LNPs in 2 minutes analysis time per sample
- Case studies and data demonstrating quantification of payloads, e.g. RNA, in LNP formulations
- Discussion on how SFA compares with methods such as the RiboGreen assay in terms of ease of use and precision of answers
- Introduction to Marama Labs’ CloudSpec instrument and how it translates into faster development times in nanomedicine development
- Q&A session where participants can interact with industry experts, gaining deeper insights into the practical applications and potential of SFA
Key Insights:
- Parkinson’s & Alzheimer’s Disease: Navigating current challenges and exploring emerging treatment breakthroughs.
- Crossing the Blood-Brain Barrier: Innovative approaches to drug delivery in the central nervous system.
- AAV-Based Gene Therapies: The promise and pitfalls of gene therapy for neurological conditions.
- Precision & Personalized Neurology: Tailoring treatments to individual patient profiles for maximum impact.
- Biomarker Discovery: Advancing early diagnosis and progression monitoring for neurodegenerative diseases.
About the Speaker
Dr. Bruce Morimoto brings decades of leadership in neuroscience drug development. At Fuku Biotech, he spearheads programs that push the boundaries of innovation and patient-centric care. This session offers a rare opportunity to hear his direct insights on the current state — and future — of neurotherapeutic R&D.
Webinar Leader
Dr. Bruce Morimoto
Head of Drug Development at Fuku Biotech.
You May Also Be Interested In…
Learn More About Neuroscience
- The Most Comprehensive Way to Search the Neuroscience Drug Development Landscape: Unique search ontologies based on Neuroscience drug and trial characteristics
- Market Leading Approach to Neuroscience Preclinical & Clinical Data Curation: Manual curation of key Neuroscience research and development data points by Neuroscience research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Neuroscience company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
